Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy
Z Ma, LZ Wang, JT Cheng, WST Lam, X Ma… - Antioxidants & redox …, 2021 - liebertpub.com
Significance: Hypoxia is emerging as a crucial regulator of the tumor microenvironment; it
governs the metastatic potential of multiple primary cancers. It is also potentially involved in …
governs the metastatic potential of multiple primary cancers. It is also potentially involved in …
Actin-bundling proteins in cancer progression at a glance
RP Stevenson, D Veltman… - Journal of cell …, 2012 - journals.biologists.com
Cells use their cytoskeletons to move, polarise, divide and maintain organisation within
multicellular tissues. Actin is a highly conserved essential building block of the cytoskeleton …
multicellular tissues. Actin is a highly conserved essential building block of the cytoskeleton …
Ral GTPases and cancer: linchpin support of the tumorigenic platform
BO Bodemann, MA White - Nature Reviews Cancer, 2008 - nature.com
A confluence of recent observations has indicted the Ras-family G-proteins RALA and RALB
as key offenders in the subversion of core biological systems driving oncogenic …
as key offenders in the subversion of core biological systems driving oncogenic …
[HTML][HTML] Discovery and characterization of small molecules that target the GTPase Ral
Abstract The Ras-like GTPases RalA and RalB are important drivers of tumour growth and
metastasis. Chemicals that block Ral function would be valuable as research tools and for …
metastasis. Chemicals that block Ral function would be valuable as research tools and for …
RAL GTPases: biology and potential as therapeutic targets in cancer
C Yan, D Theodorescu - Pharmacological reviews, 2018 - pmc.ncbi.nlm.nih.gov
More than a hundred proteins comprise the RAS superfamily of small GTPases. This family
can be divided into RAS, RHO, RAB, RAN, ARF, and RAD subfamilies, with each shown to …
can be divided into RAS, RHO, RAB, RAN, ARF, and RAD subfamilies, with each shown to …
CD24 is an effector of HIF-1–driven primary tumor growth and metastasis
S Thomas, MA Harding, SC Smith, JB Overdevest… - Cancer research, 2012 - AACR
Hypoxia drives malignant progression in part by promoting accumulation of the oncogenic
transcription factor hypoxia inducible factor–1α (HIF-1α) in tumor cells. Tumor …
transcription factor hypoxia inducible factor–1α (HIF-1α) in tumor cells. Tumor …
Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase …
Y Wu, MS Siadaty, ME Berens, GM Hampton… - Oncogene, 2008 - nature.com
Cell migration is essential to cancer invasion and metastasis and is spatially and temporally
integrated through transcriptionally dependent and independent mechanisms. As cell …
integrated through transcriptionally dependent and independent mechanisms. As cell …
The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras
Y Gus-Brautbar, D Johnson, L Zhang, H Sun, P Wang… - Molecular cell, 2012 - cell.com
The connection between cancer and inflammation is widely recognized, yet the underlying
molecular mechanisms are poorly understood. We report here that TIPE2 provides a …
molecular mechanisms are poorly understood. We report here that TIPE2 provides a …
[HTML][HTML] Ral small GTPase signaling and oncogenesis: more than just 15 minutes of fame
Since their discovery in 1986, Ral (Ras-like) GTPases have emerged as critical regulators of
diverse cellular functions. Ral-selective guanine nucleotide exchange factors (RalGEFs) …
diverse cellular functions. Ral-selective guanine nucleotide exchange factors (RalGEFs) …
The RalGEF-Ral effector signaling network: the road less traveled for anti-Ras drug discovery
NF Neel, TD Martin, JK Stratford, TP Zand… - Genes & …, 2011 - journals.sagepub.com
The high frequency of RAS mutations in human cancers (33%) has stimulated intense
interest in the development of anti-Ras inhibitors for cancer therapy. Currently, the major …
interest in the development of anti-Ras inhibitors for cancer therapy. Currently, the major …